![BioCentury This Week artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts123/v4/fb/22/95/fb22950f-4f1e-4c27-1678-e9d26780c410/mza_11443144383013806162.jpg/100x100bb.jpg)
Ep. 118 - Bio€quity Recap, Part 1
BioCentury This Week
English - May 18, 2022 00:00 - 22 minutes - 15.6 MB - ★★★★★ - 11 ratingsScience biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Ep. 117 - Sofinnova Partners’ Growth Deal, Plus Distillery on Tap
Next Episode: Ep. 119 - Bio€quity Recap, Part 2
Even as industry is facing a global talent crunch, Europe’s biotechs have it better than ever, Medicxi’s Francesco De Rubertis said on a special edition of the BioCentury This Week podcast recapping the first two days of the Bio€quity Europe conference in Milan. He and MSD’s Khatereh Ahmadi joined the BioCentury podcast team to discuss the battle for top talent and the state of deal-making amid the ongoing downturn. This week’s podcast is sponsored by MSD (Merck & Co. Inc. in the U.S.), whose London-based European Innovation Hub includes a business development and licensing team, clinical teams and its U.K. Discovery Research Centre. For more information visit, msd.com/licensing.